Podcasts about semaglutide

GLP-1 drugs were first approved to treat diabetes and then caused a frenzy when it was discovered they were great for weight loss. But now scientists are discovering the drugs that have brand names including Ozempic and Mounjaro might offer so much more, from reducing the risk of heart attack to treating kidney disease. Today, Doctor Paul Joyce, a pharmaceutical scientist at Adelaide University on how Ozempic is shaking things up, again. Featured:  Doctor Paul Joyce, a pharmaceutical scientist at Adelaide University 

Semaglutide. Tirzepatide. Retatrutide. The peptide conversation has taken over every gym, group chat, and social media feed. But the part about muscle loss, osteopenia, and what the gray market is actually selling you? That part is getting buried. Chalene Johnson sits down with Adam Schafer, co-host of Mind Pump, one of the top fitness podcasts in the world with nearly half a billion downloads. Adam spent three and a half years running real test groups on GLP-1s including Ozempic and Wegovy. What he found changed his perspective entirely and he is not holding back. This conversation covers what is actually driving muscle and bone density loss in women over 40 and 50, why the scale and the mirror are lying about body composition, and what most women are getting wrong about building real strength in midlife. Plus the truth about the gray market and what those peptides may actually contain. This is the conversation the fitness industry is not having and it is one every woman over 40 needs to hear.

In part two of the GLP-1 series, Melissa gets practical. What does it actually feel like to be on this medication? What does responsible use look like day to day? And how do you get the best results at the lowest effective dose possible?Whether you just started, you're a few months in, or you're wondering why you're not seeing the results you expected — this episode is for you.IN THIS EPISODE, YOU'LL LEARN:Why you forget about food on a GLP-1 and why that feeling of relief is also where your responsibility beginsWhat the flat affect actually is, why it happens, and what it tells you about your doseWhy GLP-1 receptors live in the brain's reward center — and what that means for your dopamine, your drive, and your nervous systemThe difference between microdosing and the lowest effective dose (and why that distinction matters more than the label)FDA-approved dosing for semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) — and where Melissa would actually startWhy digestion has to come first before or while on this medicationThe truth about blood sugar stability on a GLP-1 and why the medication doesn't do that work for youWhy women on GLP-1 are losing muscle without realizing it — and exactly what to do about itProgressive overload: what it actually means and why going through the motions isn't enoughWhy Melissa recommends Cronometer over MyFitnessPal for tracking on a GLP-1Hair loss — medication side effect or weight loss side effect? Melissa breaks down the differenceFatigue — why it's actually both, and what to do depending on which one it isWhy perimenopause symptoms can get louder on a GLP-1 and what's happening hormonallyHow to know if you're actually at a plateau (hint: four weeks is the threshold)What to do when you're at max dose and the scale still isn't movingHow long is it okay to stay on a GLP-1 — and what the long-term concerns actually areTIMESTAMPS:00:00 — Welcome back + recap of episode one 01:45 — What it actually feels like when you first start 03:30 — The flat affect and the dopamine loop 07:50 — Strength training as a natural dopamine regulator 10:00 — The lowest effective dose and what microdosing actually means 12:00 — Semaglutide dosing overview (Wegovy, Ozempic) 13:45 — Tirzepatide dosing overview (Zepbound, Mounjaro) 15:00 — How to advocate for a lower starting dose with your provider 16:00 — Melissa's personal experience: 1 mg tirzepatide for inflammation 23:30 — Making the medication work hard for you: the foundation 25:00 — Digestion first — why gut health matters before you start 26:30 — Blood sugar stability is your responsibility 29:00 — Protein first, always 31:00 — Why women on GLP-1 are losing muscle 33:30 — Progressive overload — what it actually looks like 35:00 — Track your food — why Cronometer and why it's non-negotiable 38:30 — Side effects: medication vs. weight loss (two different categories) 39:00 — Hair loss explained 40:50 — Fatigue explained 42:00 — Nausea, constipation, gut symptoms 42:45 — Perimenopause, hormonal shifts, estrogen dominance44:30 — How to know if you're actually at a plateau 48:00 — Max dose: what to do when you're there 48:30 — How long is it okay to stay on a GLP-51:00 — Download the GLP-1 Support Guide + closeRESOURCES:Download the GLP-1 Support Guide — everything you need to use this medication responsibly: workouts with logging space, protein meal plan, nutrition framework, and tracking tools. melissaeichwellness.com/GLP1guideBook a free consultation with Melissa — whether you're considering GLP-1, already on it, or wanting gut or hormone support while on it: https://melissaeichcoaching.practicebetter.io/#/6490bd200e37c64b346b25c8/bookings?s=6a0cb936104f4243883a46dfGut Healing Program or Complete Hormone Program: https://melissaeichcoaching.practicebetter.io/#/6490bd200e37c64b346b25c8/bookings?s=69fe864f4b36932a1ec4aba4Related episodes:Episode [#179]: GLP-1 Series, Part 1 — The Shame, the Gray Area, and Weight Loss Resistance: https://podcasts.apple.com/us/podcast/179-glp-1-for-midlife-women-where-to-begin-part-1-3/id1650475536?i=1000771142749DUTCH test series — perimenopause, weight loss resistance, and estrogen detox - https://podcasts.apple.com/us/podcast/176-perimenopause-weight-gain-and-the-dutch-test/id1650475536?i=1000767363294CONNECT WITH MELISSA:Instagram: @melissa_eich Website: melissaeichwellness.com Email: melissa@melissaeichwellness.comABOUT THE SHOW:Body-Led by Design is a podcast for women who are done guessing and ready to understand what's actually happening in their bodies. Hosted by Melissa Eich, registered nurse, hormone and nervous system coach, and somatic practitioner, each episode brings the real conversations from her practice so you can walk away more informed, more empowered, and a little less alone in what you're navigating.LEAVE A REVIEW:If this episode resonated with you, a five-star review means the world. It helps more women find this podcast and get the information they actually need.SEO KEYWORDS:GLP-1 side effects, semaglutide weight loss, tirzepatide lowest effective dose, microdosing GLP-1, hair loss on Ozempic, muscle loss GLP-1, weight loss plateau GLP-1, GLP-1 fatigue, Wegovy responsible use, perimenopause GLP-1, how long to stay on GLP-1, GLP-1 support women over 40

GLP-1 stopped working? Or is your body trying to tell you something deeper?In this episode, Kylie unpacks the REAL reason so many women hit a weight loss plateau while taking Ozempic, Mounjaro, Semaglutide or Tirzepatide… and why the answer is NOT always “eat less” or “increase your dose.”You'll learn: • Why GLP-1 plateaus happen • The hidden danger of losing muscle while dieting • How chronic stress and cortisol can stall fat loss • Why blood sugar regulation matters more than calories alone • The truth about “metabolic damage” • How under-eating protein can slow your progress • Why your nervous system affects the scale more than you think • The biggest mistakes women make when their appetite drops • How to support your metabolism WITHOUT spirallingThis episode is a must-listen for women over 40 who feel frustrated, stuck, inflamed, exhausted, or scared that their body has “stopped responding.”Because your body isn't broken, babe. It's adapting.And once you understand what's really happening beneath the surface… everything changes.

Quando si parla di Ozempic, Wegovy e Mounjaro, quasi tutti si concentrano sulla stessa cosa: il peso che scende.Ma c'è una domanda molto più interessante che quasi nessuno si pone. Cosa succede quando questi farmaci vengono abbinati alla dieta chetogenica?Perché sulla carta sembra una combinazione perfetta. Entrambi aiutano a controllare la glicemia. Entrambi migliorano la sensibilità insulinica.Entrambi possono favorire il dimagrimento. Eppure proprio qui si nasconde uno degli errori più pericolosi ⚠️ In questo episodio il Dott. Lorenzo Vieri analizza una delle combinazioni più discusse degli ultimi anni: dieta chetogenica e farmaci GLP-1 agonisti come Ozempic, Wegovy e Mounjaro.Scoprirai perché questa strategia può dare risultati estremamente interessanti, ma anche perché può trasformarsi rapidamente in un problema se non viene gestita correttamente. Perché il rischio non è soltanto perdere peso. Il rischio è perdere troppo peso, troppo in fretta e soprattutto perdere massa muscolare

How fast does semaglutide work? The short answer is that many people will lose weight in the first week of taking semaglutide if they make lifestyle changes (e.g., increased physical activity and reduced-calorie diet). Remember, the first 4 doses are small and are primarily used to gently introduce the peptide to the body without risking stomach-related side effects. It's important to understand that it's possible to "out-eat" any weight loss medication. So, you may see little to no weight loss in the early weeks without making lifestyle changes.  Read the Full Episode Transcript: https://pepties.com/faqs-about-semaglutide/ Related Links/Products Mentioned: Peptide Podcast Partners Page https://pepties.com/partners/ Buy Peptides online at BioLongevity Labs: Use our link and enter COUPON CODE: PEPTIDEPODCAST  at checkout to receive 15% off your total order:  https://go.biolongevitylabs.com/SH5C Momentous Supplements (we use Creatine, Vital Aminos, Whey Protein) https://crrnt.app/MOME/OqGQOxGA LMNT – More Salt, Not Less.  https://elementallabs.refr.cc/default/u/johnjavit Thorne Supplements (we use Omega-3 with CoQ10, Red Yeast Rice, Zinc) https://get.aspr.app/SH1KvW Organifi Creatine and Shilajit Gummies http://rwrd.io/rlbkajm?c MitoZen (methylene blue for Cognitive Function, Anti-Aging, Mental Clarity) https://www.mitozen.com/ref/cnlwiztypt/ For skin and hair health (Copper Tripeptide-1)  Visit Luminose by Entera for an exclusive offer for Peptide Podcast listeners!  ** Promo code PEPTIDEPODCAST at checkout for 10% off an order or 10% off the first month of a subscribe-and-save. ** https://www.enteraskincare.com/?rfsn=8906839.f93c72 NAD+ Push Patch: https://www.pushpatch.com/

Nutritionist Leyla Muedin discusses research showing simple strength tests—grip strength and a five-rep sit-to-stand chair test—predict longevity in older women. In a University at Buffalo study of over 5,000 women ages 63–99 followed for eight years, stronger grip and faster chair-stand times were linked to lower mortality; every additional 7 kg of grip strength corresponded to a 12% reduction in death risk, and faster chair-stands were also associated with improved survival, even after adjusting for activity, cardiovascular fitness, and inflammation. She emphasizes prioritizing muscle-strengthening alongside aerobic exercise and suggests accessible resistance options (weights, bodyweight moves, or household items) with professional guidance as needed. She then cites UK Biobank data linking long-term statin use to declines in grip strength and appendicular lean mass, urging discussion with physicians and added vigilance, especially for those also using GLP-1 drugs that may reduce protein intake and muscle mass.

What if the newest “miracle” weight loss prescription is hiding the SAME root problem as Ozempic?Retatrutide is being called the next-generation fat loss breakthrough… promising even MORE dramatic results than Ozempic. But before you jump on the hype, there's something no one is talking about.Could rapid weight loss come at the expense of your metabolism, muscle mass, hormones, and long-term health?Watch until the end before deciding if Retatrutide is really “better.” Supplements Featured In This Episode:• Acceleradine® Iodine https://www.acceleratedhealthproducts.com/products/acceleradine-iodine-supplement  • Accelerated Methylene Blue® https://www.acceleratedhealthproducts.com/products/accelerated-methylene-blue-supplement • Accelerated Thyroid® https://www.acceleratedhealthproducts.com/products/accelerated-thyroid-supplement • Accelerated Fast® https://www.acceleratedhealthproducts.com/products/accelerated-fast-supplement • Accelerated Liver Care® https://www.acceleratedhealthproducts.com/products/accelerated-liver-care• Accelerated Cellular Detox® Powder https://www.acceleratedhealthproducts.com/products/accelerated-cellular-detox-powderNot sure what food to eat and avoid? This guide is for you.⬇️

Can topical B12 help relieve itching?The types of doctors to avoidGetting back to basicsA case study of lavender oil helping to relieve itchingYou say you're dairy sensitive but you use whey protein. Please explain.What are your thoughts on a lactose relief patch that is on offer?

Welcome to the latest episode (June 2026) of Diabetes Core Update, where every month Neil Skolnik, MD and John Russell, MD review the most important articles on diabetes, obesity, and cardiometabolic disease. This month on DOC Update: Shah S, et al. "Food Coloring Additives and Incidence of Type 2 Diabetes in the NutriNet-Santé Prospective Cohort Diabetes Care. 2026;49(6):1067–1077. doi.org/10.2337/dc25-2727 Hespanhol L, et al. "Automated Insulin Delivery Systems in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis." Diabetes Care. 2026;49(6):1134–1143. doi.org/10.2337/dc25-2435 Tatum K, et al. "Survival and Recurrence With GLP-1 Receptor Agonists in Breast Cancer." JAMA. Published Online: May 11, 2026 2026;9;(5):e2612133. doi:10.1001/jamanetworkopen.2026.12133 Winkler C, et al. "Screening Children for Early-Stage Type 1 Diabetes." JAMA. Published Online: May 21, 2026 doi:10.1001/jama.2026.6085 Würtz Yazdanfard P, Kosjerina V, Wood-Kurland H et al. "Effectiveness and Safety of Semaglutide in Type 1 Diabetes: A Danish Nationwide Cohort Study (2018–2024)" Lancet. Volume 66, 101716, July 2026. doi:10.1016/j.lanepe.2026.101716 Horn D, Aronne L, Wharton S et al. "Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial." Lancet. Published online May 12, 2026. doi:10.1016/S0140-6736(26)00656-2 Presented by: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John J. Russell, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Chair-Department of Family Medicine, Abington Jefferson Health For information about the American Diabetes Association's scholarly journals, visit diabetesjournals.org. For more about this podcast, click here.

Taylor and I are back for another Reader Mailbag. This one covers a lot of ground.We start with anhedonia on GLP-1s because the questions on this have been nonstop. People are experiencing it on Semaglutide, Tirzepatide, and Retatrutide and we break down why it happens, whether it is dose related, and what you can actually do about it.From there we get into the Reta and heart rate debate, Taylor's GLP rotation strategy, and whether the cardiovascular tradeoffs are actually worth worrying about.Then Taylor takes over for the hormone optimization section for young women in their twenties and thirties. Her personal story on this one is worth watching alone.We also cover accidental peptide overdoses, what to do when it happens, and finish with teen acne solutions using peptides and topicals.Submit your questions for the next episode at the link below.For research and entertainment purposes only.Links, cheatsheet, private group and more

Negli ultimi anni sono ovunque.In televisione.Su TikTok.Nelle cliniche.Nei podcast.Perfino nelle conversazioni quotidiane.Ozempic. Wegovy, Munjaro. Semaglutide.I farmaci dimagranti di cui tutti parlano ⚠️C'è chi li considera una rivoluzione.Chi li demonizza completamente.E chi li usa senza avere davvero idea di cosa stiano facendo dentro il proprio corpo.Ma allora… qual è la verità?In questo episodio il Dott. Lorenzo Vieri affronta uno degli argomenti più discussi del momento: i farmaci GLP1 agonisti

In this episode, we break down the science behind GLP-1 medications including Ozempic, Wegovy, Zepbound, Mounjaro, semaglutide, and tirzepatide. Learn how GLP-1 weight loss medications work, their role in appetite suppression, insulin regulation, metabolic health, obesity treatment, and type 2 diabetes management.This evidence-based discussion explores GLP-1 benefits, side effects, muscle loss concerns, weight regain after stopping medication, nutrition considerations, digestion, metabolic adaptation, and sustainable wellness strategies. If you're considering GLP-1 medications or simply want a smarter conversation about obesity medicine, weight loss, longevity, and metabolic health, this episode delivers a clinically grounded wellness perspective. Disclaimer: This podcast is for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. The views shared are intended to support informed wellness conversations and should not replace individualized guidance from your physician or qualified healthcare provider. Always consult your healthcare team before making decisions regarding medications, treatment, nutrition, or health management.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Recent updates offer a fascinating glimpse into an industry marked by dynamic shifts and groundbreaking advancements, each promising to reshape the future of healthcare. Let's delve into some of the most notable developments that are capturing attention across the globe. Starting with Eli Lilly's obesity medication, Zepbound, which has regained insurance coverage through CVS Caremark. This decision is emblematic of a broader recognition of obesity as a significant health issue that demands comprehensive treatment solutions. The reinstatement of coverage enables more patients to access Zepbound, potentially setting a benchmark for other insurers and leading to improved health outcomes. Shifting focus to oncology, AbbVie has secured FDA approval for a new therapy derived from its acquisition of ImmunoGen, adding to its portfolio of antibody-drug conjugates (ADCs) with Elahere. This development underscores the escalating value of ADCs in precision cancer therapies, offering innovative solutions for targeting cancer cells while preserving healthy tissues. Japan's pharmaceutical R&D stance is under examination as Prime Minister Sanae Takaichi meets with over 20 industry leaders to discuss maintaining the nation's competitive edge. This gathering highlights a global race among nations to enhance their R&D capabilities, ensuring leadership in pharmaceutical innovations. In neuroscience, Novartis's relentless pursuit to conquer the blood-brain barrier reflects ongoing efforts to revolutionize treatments for neurological disorders. Despite recent advancements, Novartis continues to explore new strategies for drug delivery to the brain, aiming to unlock therapies for conditions like Alzheimer's and Parkinson's disease. Viridian Therapeutics' collaboration with Wuxi Biologics marks a notable push in the eye drug market, positioning them against major players like Amgen. This partnership emphasizes manufacturing capability as a critical factor in ensuring resilient supply chains and competitive advantage. The hepatitis B treatment landscape has witnessed significant progress with GSK's phase 3 trial results for its drug Bepirovirsen. Achieving a functional cure in around one-fifth of patients signifies a major step forward in addressing this widespread disease. The potential to reduce lifelong antiviral therapy and lower liver cancer rates illustrates the transformative impact of nucleic acid-based therapies. Leadership dynamics also play a crucial role in pharma strategies. PharmaEssentia's appointment of Eric Vogel highlights the industry's reliance on seasoned talent to drive market expansion and broaden therapeutic indications, particularly for its rare blood cancer drug Besremi. In longevity research, Human Longevity's collaboration with Insilico Medicine introduces Human Life Foundation Models (HLFM), leveraging AI and genomics to extend human lifespan. This initiative is part of a broader trend integrating cutting-edge technologies into healthcare research, reflecting an evolving focus on longevity and genomic sciences. Regulatory landscapes are also evolving, as seen with CMS finalizing changes to the No Surprises Act dispute resolution process. By streamlining arbitration amidst rising disputes, these updates aim to refine healthcare policy frameworks for more efficient stakeholder service. Meanwhile, biosimilar approvals are gaining traction globally. ANVISA's approval of EMS's Ozivy in Brazil introduces a cost-effective alternative to Novo Nordisk's semaglutide (Ozempic) for type 2 diabetes. This step enhances access to affordable diabetes treatments, crucial for managing this prevalent metabolic disorder. In clinical trials innovation, D&D Pharmatech's Zabopegdutide has shown promising Phase 2 results for metabolic dysfunction-associated steatohepatitis (MASH), indicating fibrosis improvement and potential disease resolution. These findings underscore dual receptor agonists' therapeutic promise in tackling complex metabolic conditions. Additionally, Kailera Therapeutics' KAI-4729 demonstrates significant weight loss in Phase 1 obesity trials, potentially reshaping the obesity treatment landscape by offering superior weight management options compared to existing therapies. Funding rounds like Secretome Therapeutics' successful $30 million Series A highlight ongoing investments in regenerative medicine and cell-based therapies, propelling advancements in cardiovascular disease treatment pipelines. The acquisition landscape remains active with CordenPharma's purchase of AmbioPharm, expanding peptide manufacturing capabilities across U.S. and China markets. This move meets growing demand for peptide APIs vital in drug development processes. Technological innovation remains pivotal as Biohub releases an AI World Model for protein biology to expedite therapeutic discovery processes. This tool exemplifies computational biology's integration into drug discovery efforts, enhancing efficiency and innovation. Overall, these developments illustrate a vibrant pharmaceutical and biotech landscape characterized by scientific breakthroughs, strategic partnerships, regulatory achievements, and technological advancements—all aimed at advancing patient care and expanding therapeutic possibilities across diverse medical domains. As these trends continue unfolding, they promise not only improved treatment outcomes but also a more robust global healthcare ecosystem committed to innovation and excellence. Thank you for tuning into Pharma Daily; stay informed as we continue bringing you the latest from this rapidly evolving industry.Support the show

I am happy to connect with Dr. William Li today! He is a world-renowned physician, scientist, speaker, and author. He is known for leading the Angiogenesis Foundation, and his groundbreaking work has impacted more than 70 diseases. He is also a Ted-X speaker and the author of Eat to Beat Your Diet, one of my favorite books thus far this year.  Dr. Li's latest book is about what happens in the body, how it should operate, and the steps we can take to restore it to its hard-wired state. We dive into how body fat impacts our health, the role of metabolism throughout our lifetime, the differences between the three fat-impacting hormones, including leptin, adiponectin, and resistin, and gender differences. We speak about new drugs like Ozempic and Semaglutide, the role of brown fat, the impact of the microbiome and specific bacteria, and nutrition and lifestyle. IN THIS EPISODE YOU WILL LEARN: Why Dr. Li chose this time to write his latest book  Is 60 the new 20? The four stages of metabolism hardwired into each of us  How excess body fat derails metabolism, and how can we unleash our inner metabolism Why is it better to eat slowly? Why should we learn to respect and tame our fat instead of hating or fearing it? Dr. Li shares his views on new prescription drugs like Ozempic and Semaglutide. Interesting facts about body fat Changes that occur in our body fat distribution as we get older How can we help our bodies fight excess body fat, bring our inner metabolism to the surface, and reduce inflammation by being aware and mindful? Modern-day lifestyle choices and metabolic disease Dr. Li discusses the interplay between the gut microbiome and metabolism, as well as the role of Akkermansia.  Some everyday foods contain natural chemicals that can activate our body's defenses, tame metabolism, and fight body fat. BIO William W. Li, MD, is an internationally renowned physician, scientist, and New York Times bestselling author of the forthcoming book “Eat to Beat Your Diet: Burn Fat, Heal Your Metabolism, Live Longer”. His groundbreaking work has led to the development of more than 30 new medical treatments and impacts care for more than 70 diseases, including cancer, diabetes, blindness, heart disease, and obesity. His TED Talk, “Can We Eat to Starve Cancer?” has garnered more than 11 million views. Dr. Li has appeared on Good Morning America, CNN, CNBC, LIVE with Kelly and Ryan, and the Rachael Ray Show, and he has been featured in USA Today, Time Magazine, The Atlantic, and O Magazine. He is the president and medical director of the Angiogenesis Foundation. Connect with Cynthia Thurlow Follow on X, Instagram & LinkedIn Check out Cynthia's website. Submit your questions to support@cynthiathurlow.com  Join other like-minded women in a supportive, nurturing community: The Midlife Pause/Cynthia Thurlow.  Purchase Cynthia's book, The Menopause Gut. Cynthia's Intermittent Fasting Transformation Book The Midlife Pause Supplement Line Connect with Dr. William Li On his⁠ website⁠ Social media: @DrWilliamLi Dr. William Li's latest book, ⁠Eat to Beat Your Diet: Burn Fat, Heal Your Metabolism, and Live Longer⁠ is available from most bookstores.

Highlights from Dr. Hoffman's Scandinavian tripShould I eliminate the nightshade family of foods from my diet?My friend has been experiencing acid reflux since using a reverse osmosis water filtration system

Book a free consultation call with Robert Sikes to break through your keto or low carb plateau right here: https://www.ketobodybuilding.com/callSurviving childhood morbid obesity and a fifteen year meth addiction takes total metabolic repair. In episode 886 of the Savage Perspective Podcast, host Robert Sikes sits down with Elaina Wang to share a powerful story of survival and deep health recovery. This discussion reveals how severe insulin resistance and bad food rules created a massive drug habit just to feel energy. Getting clean from drugs was brutal, but finding the keto diet and reversing type two diabetes naturally changed her entire life. You will learn exactly how real nutrition, heavy weight lifting, and targeted peptides can heal your brain, stop cravings, and fix chronic pain after years of severe trauma and addiction.Elaina's Hack Your Health Coaching: https://hackyourhealthcoaching.com/elaina-wangElaina's FB: https://www.facebook.com/KetoWang/Get Keto Brick: https://www.ketobrick.com/Subscribe to the podcast: https://open.spotify.com/show/42cjJssghqD01bdWBxRYEg?si=1XYKmPXmR4eKw2O9gGCEuQChapters0:00 - How I Survived Childhood Obesity & Severe Insulin Resistance1:09 - Why I Started Meth: The Shocking Truth About Energy & Fatigue2:01 - The Food Pyramid Myth: How Government Guidelines Fueled Addiction3:47 - Unbreakable Confidence: How to Build Self-Esteem When Overweight6:14 - The "Fat Meth Addict": Why Stimulants Couldn't Fix Type 2 Diabetes8:17 - Meth vs Cocaine: How Drugs Hijack Brain Dopamine & Sugar Cravings11:08 - The Secret Life of a Functional Addict: Survival Tactics & Thefts13:36 - Toxic Relationships: Navigating Co-Dependency & Addiction Relapse17:03 - The Turning Point: Dodging the Cops & Deciding to Get Clean20:43 - Type 2 Diabetes Diagnosis at 24: Ignoring the Ultimate Warning Sign21:10 - Quitting Meth Cold Turkey: The Brutal Reality of Early Sobriety25:22 - Blood Sugar at 426: Why I Refused Insulin Due to Addiction Fears27:08 - Reversing Type 2 Diabetes Naturally with the Keto Diet28:24 - Keto & Neuroplasticity: The Ultimate Biohack for Addiction Recovery30:02 - Losing 80 Lbs Fast: Do Cigarettes Spike Your Blood Sugar?34:00 - Becoming a Keto Coach: The Evolution of Low-Carb & Carnivore Diets36:10 - Healing Trauma vs. Trauma Bonding: The Missing Link in Weight Loss41:17 - BPC-157 & TB-500: Can Peptides Cure Chronic Pain & Bursitis?45:13 - GLP-1 for Addiction: The Unbelievable Cure for Alcoholism & OCD49:02 - Semaglutide vs Tirzepatide: Which GLP Weight Loss Peptide is Best?51:49 - The Dark Side of Ozempic: Who Should NEVER Take GLP Peptides53:31 - 155 Lb Weight Loss Surgery: Is Medical Tourism in Tijuana Safe?57:11 - Tummy Tuck Complications: Hematomas, Wound Vacs & Honest Recovery1:01:01 - "Am I Too Old to Get Healthy?" The Ultimate Mindset Shift for Men & Women1:05:26 - Where to Find Elaina Wang: Coaching, Biohacking & Future Events

Dr. Mindy talks about Crab Boils. And then she answers questions about numb tongue, why do men age so well, tennis elbow, Adderall, side effects of Semaglutide, how many grams of fiber do you need, NAD formulations, allergy headaches, blurred vision with Tirzepatide, lump on a toddler's chin, ice cold feet, another Adderall question, grey hair, tally-whackers and loud tummy noises. https://www.youtube.com/@TheDrMindyExperiment See omnystudio.com/listener for privacy information.

Peptides are everywhere right now but most people still don't understand how they actually work.In this episode of Under Contract, we sit down with Dr. Gabriel Alizaidy to break down the science behind peptide therapy, GLP-1 medications, if retatrutide works for weight loss, recovery stacks, and the truth about biohacking trends dominating social media.We discuss how peptides can support weight loss, inflammation, healing, hormone balance, mitochondrial health, longevity, and performance, but also why most people are using them incorrectly.Topics include: • GLP-1 medications like Semaglutide and Tirzepatide • Why peptide therapy should be medically supervised • The “Wolverine Stack” for recovery: BPC-157 + TB-500 • Copper peptides and the “copper uglies” explained • Peptides for sleep, fat loss, muscle retention, and high performance • Hormones, mitochondria, and why bloodwork matters before starting • Common peptide mistakes people make from TikTok advice • Longevity, anti-aging, and optimizing your health safelyIf you're curious about GLP-1s, peptide stacks, anti-aging protocols, or how peptides are changing medicine, this conversation breaks down what's real, what's hype, and what to know before trying them.Connect with Dr. Alizaidy on Instagram: @gabrielalizaidy#Peptides #GLP1 #Biohacking #Longevity #WeightLoss #HormoneOptimization #AntiAging #Recovery #HealthPodcast #WellnessPodcast

Nutritionist Leyla Muedin discusses a listener question about whether agave nectar can contribute to obesity like high-fructose corn syrup, arguing that regular use of sweeteners—including agave, honey, monk fruit, stevia, aspartame, sucralose, allulose, and sugar alcohols—can maintain sweet cravings, spike insulin, and contribute to weight-loss plateaus, with added concerns such as microbiome effects, GI upset, and aspartame's neurotoxicity. She notes insulin's role in fat storage and blood pressure via sodium retention, and suggests that needing a sweetener in coffee or tea may indicate dependence on sweetness. She then covers a newly developed, validated Food Noise Questionnaire (FNQ) published in Obesity to measure intrusive food-related rumination, highlighting its five Likert-scale items, study sample characteristics, and the need for further research, including effects of GLP-1 drugs.

More on “eat the rainbow” . . . or notMedical breakthroughs that we don't really needCan you discuss the order of eating macronutrients and its impact on blood glucose?What about the impact of apple cider vinegar on blood sugar?

Are GLP-1 medications like Semaglutide, Tirzepatide, and Retatrutide helping or hurting your recovery? In this episode I cut through the hype and fear to talk about the real dangers people aren't discussing, how these medications should actually be used, and why no tool can replace healing your relationship with food. If you're considering a GLP or already using one, this is an important conversation you need to hear.Grab your copy of my FREE 9 page Beginner's Guide to Food Sobriety https://www.foodfreedomwithmary.com/foodsobrietyguideFood Freedom Online Course: https://www.foodfreedomwithmary.com/foodfreedomcourseFood Sobriety Mini Course -https://www.foodfreedomwithmary.com/foodsobrietymcWant to learn more about me and my coaching programs? Do you need private coaching and intensive daily contact with a coach? Fill out my application so we can chat about whether or not my program is for you and which option is best for you. Payment plans available. Don't see a payment option that works for your pay schedule? Let's chat about a custom pay plan.www.foodfreedomwithmary.com/chooseyourpath Join my online community The Food Freedom Tribe! An online community of support, eduction, inspiration, accountability….. Learn more here: https://www.foodfreedomwithmary.com/tribemembership Application: https://docs.google.com/forms/d/1upnWHYK0RXfmyRTqlsF_R06z3NA8LZYHIMWFykq7-X4/viewformInstagram: www.instagram.com/coachmaryroberts Facebook: www.Facebook.com/ketomary71 Facebook group: https://www.facebook.com/groups/4915319108493196/?ref=share_group_linkWebsite: www.foodfreedomwithmary.com Join the email list.Email: mary@foodfreedomwithmary.com

Could the "weight-loss shots" everyone is talking about actually be the next big breakthrough in cancer prevention? In this week's episode of the FMI podcast, I'm joined once again by our Chief Medical Officer, Dr. Mark Holthouse. While Dr. H is a world-renowned expert in hormone health and cardiometabolic medicine, today we are diving into a topic that is reshaping the future of longevity: the direct link between obesity-related cancers and GLP-1 medications. We recently learned that colon cancer is now the leading cause of cancer death for men and women under 50. It's a sobering statistic, but there is hope in the evolving science of metabolic medicine. In this episode, we discuss: The "Four Horsemen" of Aging: Why cardiovascular disease, cancer, dementia, and insulin resistance are all driven by the same cellular pathways. GLP-1s Beyond Weight Loss: How medications like Semaglutide and Tirzepatide work at the cellular level to potentially reduce tumor volume and progression. The "New Kid on the Block": A deep dive into Retatrutide, the experimental triple-agonist showing even more dramatic results in preclinical models. Obesity-Related Cancers: Why fatty liver, chronic inflammation, and nutrient-sensing pathways (like mTOR) create a "pro-cancer milieu." The "Foundational Four": Why, despite all the medical breakthroughs, sleep, clean eating, stress management, and exercise remain the ultimate levers for health. Dr. Holthouse also shares his "minimalist" approach to detoxification and why he's more interested in "reining patients in" from expensive gadgets to focus on what actually moves the needle. Whether you are interested in the latest longevity science or simply looking for ways to lower your family's risk of chronic disease, this conversation is packed with "root cause" insights you won't want to miss.

Could GLP-1 medications be the missing piece in treating inflammatory skin disease? In this episode of Science is Skin, Dr. Ted Lain sits down with Dr. Lindsey Bordone — former Columbia University associate professor of dermatology, now in private practice at Bordone Dermatology in Scottsdale, Arizona — for a deep dive into metabolic disease and the skin. Dr. Bordone was among the first dermatologists to prescribe GLP-1 agonists for her patients, and in this conversation she explains exactly why. From the link between hyperinsulinemia and chronic inflammation to the visible skin signs of insulin resistance — skin tags, acanthosis nigricans, forearm hair loss — she makes the case that dermatologists are uniquely positioned to catch metabolic disease before any other specialty. Dr. Bordone walks through how she uses tirzepatide (Mounjaro/Zepbound), semaglutide (Ozempic/Wegovy), and the emerging triple-G drug retatrutide, including her lab protocols, dosing philosophy, how to manage GI side effects, and the surprising interaction between GLP-1s and estrogen therapy. In this episode: Why high BMI reduces biologic efficacy in psoriasis patients How to check fasting insulin (HOMA-IR) and why most physicians aren't doing it Skin signs of insulin resistance: skin tags, forearm hair loss, and neck skin thickening Tirzepatide vs. semaglutide vs. retatrutide — how to choose and when Retatrutide's remarkable 93% fatty liver clearance rate in clinical trials The truth about sarcopenia and muscle loss on GLP-1 medications Dosing protocols, side effect management, and when NOT to escalate quickly Protein intake recommendations during active weight loss Estrogen and GLP-1 synergy — what dermatologists need to know Lab work to run before and during GLP-1 therapy How to build an insurance case for continued medication coverage Resources mentioned: HOMA-IR fasting insulin/glucose testing AAD resources on metabolic dermatology Bordone Dermatology — Scottsdale, Arizona Enjoyed this episode? Share it with a colleague and leave us a five-star review. Subscribe so you never miss an episode of Science is Skin. To watch this and other episodes, be sure to check out our YouTube page DISCLAIMER: This podcast is not intended to provide diagnosis, treatment, or medical advice. Content provided in this podcast is for educational purposes only. Please consult with a physician regarding any health-related diagnosis or treatment.See omnystudio.com/listener for privacy information.

We have only recently become aware of the close relationship between the heart and the kidneys. In today's discussion, Dr. Neil Skolnik speaks with Dr. Josephine Harrington to gain insight into these newly-discovered links between cardiovascular risk and CKD. This special episode is sponsored with support from Bayer. Please listen to the episodes by clicking on the podcast player below or by freely subscribing to Diabetes Core Update via Apple Podcasts, Amazon Music, Spotify, or your preferred podcast platform. Presented by: -Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health -Josephine Harrington, M.D., Assistant Professor of Medicine in the Division of Cardiology at the University of Colorado School of Medicine. Selected references: -Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026. The American Diabetes Association's Standards of Care 2026, Diabetes Care 2026;49 (Supplement_1):S246–S260 -Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med 2020;383:2219-2229 -Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2020;383:1436-1446 -Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med 2024;391:109-121

I tried a GLP-1 for 30 days… and what happened genuinely shocked me. In this episode, I'm sharing my completely honest experience trying a GLP-1 as an emotional eating coach, including both the incredible upsides and the concerns that made me rethink the conversation happening online.We're also diving deep into the science behind: • What GLP-1s actually are • The difference between semaglutide and tirzepatide • What peptides are • Why food noise disappears • How GLP-1s slow digestion • Why protein and strength training matter SO much • The truth about hair loss on GLP-1s • Nutrient deficiencies nobody warns women about • Why these medications are NOT a long-term identity replacementThis is not an anti-GLP-1 episode.And it's not blind hype either.It's the honest conversation women deserve to hear.If you've ever wondered: “Would a GLP-1 help me?” or“Why are these medications changing people's lives?”…this episode will give you a balanced, educational, deeply personal perspective.⭐ If this episode helped you, please leave a review and share it to your Instagram stories and tag me so I can repost you!Get Kylie's exact weight loss BlueprintGet Kylie's Free Weight Loss CourseFollow Kylie on InstagramBOMBSHELL BLUEPRINT WEIGHT LOSS FOR EMOTIONAL EATERS

Could the hidden ingredients in Ozempic-style weight loss pills be damaging your gut health and slowing down your metabolism?In this episode of Accelerated Health with Sara Banta, I uncover the shocking truth behind many popular GLP-1 medications and weight loss pills — and why some of the inactive ingredients, fillers, additives, and long-term effects may be creating serious problems beneath the surface.While Ozempic and similar drugs are praised for rapid weight loss and appetite suppression, many people are experiencing gut issues, muscle loss, fatigue, nutrient deficiencies, slowed metabolism, digestive dysfunction, and rebound weight gain. I explain how these medications may affect your microbiome, blood sugar regulation, insulin sensitivity, and overall metabolic health over time.You'll also learn why protecting muscle, supporting the gut, and optimizing metabolism naturally are critical for sustainable weight loss and long-term health.If you've considered taking Ozempic, are currently using GLP-1 medications, or are struggling with unexplained digestive and metabolic issues, this episode is essential to listen to.Supplements Featured In This Episode:• Acceleradine® Iodine https://www.acceleratedhealthproducts.com/products/acceleradine-iodine-supplement  • Accelerated Thyroid® https://www.acceleratedhealthproducts.com/products/accelerated-thyroid-supplement • Accelerated Fast® https://www.acceleratedhealthproducts.com/products/accelerated-fast-supplement• Accelerated Liver Care® https://www.acceleratedhealthproducts.com/products/accelerated-liver-care• Healthy Gut Tributyrin-X https://www.acceleratedhealthproducts.com/products/tributyrin-x• Pure Encapsulations® Berberine UltraSorb™ - Blood Sugar & Metabolic Support https://www.acceleratedhealthproducts.com/products/pure-encapsulations-berberine-ultrasorb Not sure what food to eat and avoid? This guide is for you.⬇️

It's In The News - where we bring you the top diabetes stories and headlines happening now. This week, Tzield approved down to age one and over, Omnipod trials for fully closed loop, Tandem approved for pregnancy, Eversense 365 launches in Europe, generic Ozempic in Canada, an award for the T1D Barbie and more.  Announcing Community Commericals! Learn how to get your message on the show here. Don't miss our in-person events: www.diabetes-connections.com/events  Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Okay.. our top story this week: XX The U.S. Food and Drug Administration (FDA) approved Tzield (teplizumab-mzwv) for use in children in stage 2 type 1 diabetes (T1D) ages one and older. The approval expands the previous indication from those aged eight and above and was granted under a priority review process. This decision is supported by one-year data from the PETITE-T1D Phase IV study, which evaluated the safety and pharmacokinetics of Tzield in children under eight years old. Tzield was approved for use in individuals 8+ in stage 2 T1D in 2022. Since then, we have been working to expand the eligible population. This expansion effort includes individuals in stage 3 T1D, who can preserve endogenous insulin production for longer when they take Tzield and, most notably today, children in stage 2. https://www.breakthrought1d.org/news-and-updates/tzield-approved-for-children-ages-one-and-older-in-stage-2-t1d/   XX Big write up in the journal Pediatrics about screening for type 1. Citing the 2025 ADA Standards of Care in Diabetes, the opinion piece talks about how to engage the greater healthcare community.  It says: We aim to encourage the development of strategies to emphasize the importance of T1D early detection, integrate screening into routine health care encounters, and support implementation of T1D screening. Pediatricians and other primary care clinicians are well positioned for greater collaboration with the multidisciplinary team, ensuring early detection, timely intervention, and improved outcomes. https://publications.aap.org/pediatricsopenscience/article/2/2/1/207272/Type-1-Diabetes-Screening-in-Pediatrics-Putting?autologincheck=redirected   XX More info about GLP-1 drugs and people with type 1. New study shows off label use did not lead to DKA or pancreatitis in a large 1-year single-center study. Moreover, GLP-1 agonist use in people with T1D was associated with lower overall rates of hospitalization, as has occurred in type 2 diabetes Although GLP-1 agonists are not approved by the FDA for T1D management, off-label adjunctive use has risen for those with obesity. Semaglutide was the most commonly-used GLP-1 (65.5% of GLP-1 users) followed by tirzepatide (23.5%). The rest were using the older-generation drugs: liraglutide or dulaglutide. Lots more information to come on type 1 and glp 1-s in upcoming studies. https://www.medscape.com/viewarticle/use-glp-1s-type-1-diabetes-not-linked-increased-dka-2026a1000d56 XX Health Canada ‌​has approved the first generic ​version of ​Danish ⁠drugmaker ⁠Novo ‌Nordisk's Ozempic drug. In January 2026, the Canadian patent for Ozempic will expire, paving the way for cheap generic versions of the semaglutide injections that help regulate blood sugar levels and appetite. Health Canada said this generic, like existing products, is indicated to be used for the "once-weekly treatment of adult patients with Type 2 diabetes to manage blood sugar levels." With three generics on the market, Tadrous said the price could drop to about $100 or less, depending on their dose. Health Canada said it's currently reviewing eight other generic submissions by different companies and expects to make a decision on these in the next few weeks and months. https://www.cbc.ca/news/health/ozempic-generic-health-canada-9.7180566 XX  Insulet has enrolled the first participant in a pivotal study for its fully closed-loop (FCL)A automated insulin delivery (AID) system for type 2 diabetes (T2D  The participants are between 18 – 75 years of age, living with T2D and using insulin (basal-bolus or basal-only). The Company received Investigational Device Exemption (IDE) approval in March 2026 from the U.S. Food and Drug Administration (FDA). The Company plans to submit a 510(k) filing to the FDA in 2027 and launch its FCL AID system for T2D in 2028.   XX insulet Corporation (PODD) has initiated a voluntary recall of certain lots of its Omnipod 5 insulin delivery Pods in the U.S. after detecting that some devices had a manufacturing defect that causes insulin leakage.   Patients using the affected devices could risk experiencing high blood glucose levels due to insufficient insulin delivery, the Acton, Massachusetts-based MedTech disclosed in a statement late Thursday. The company has already notified the FDA about the recall, which it said will affect nearly 1.5% of Omnipod 5 pod units it manufactures annually. The customers were advised to immediately seek a product replacement at no cost if a Pod from a defective lot is currently in use. https://www.msn.com/en-us/money/companies/insulet-recalling-certain-defective-omnipod-insulin-delivery-devices/ar-AA1YyslT?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1&bundles=feat-es2020-c XX Tandem Diabetes Care (Nasdaq:TNDM) gets FDA clearance for its automated insulin delivery (AID) technology for use in pregnancy. The FDA cleared the company's Control-IQ AID technology for use in what they call: pregnancy complicated by type 1 diabetes mellitus. Tandem says t:slim X2 and Mobi are the first and only commercially available AID systems cleared for use during pregnancy in the U.S. https://www.drugdeliverybusiness.com/tandem-fda-clearance-aid-pregnancy-t1d/ XX Tandem also issued an urgent medical device correction for a software problem with its Mobi insulin pumps. The malfunction may cause insulin delivery to stop, causing high blood sugar if not addressed, the Food and Drug Administration said in a Wednesday recall notice. We told you about this back in October when Tandem sent a letter to customers notifying them of the fault and instructing them to update their pump software as soon as possible. The FDA now issued a class one recall, the most serious type. We just released a bonus episode all about Tanem – tubeless mobi and what else is in the pipeline. You can listen to that wherever you are listening to this.. it's the episode just before this one. https://www.medtechdive.com/news/tandem-recalls-mobi-insulin-pumps-over-software-malfunction/818260/   XX Switching CGMs didn't make a measurable difference for adults using MiniMed's pump system. In a real-world analysis presented at the International Conference on Advanced Technologies & Treatments for Diabetes, researchers found that CGM metrics for patients who switched from the Guardian 4 sensor (MiniMed) to Instinct by Abbott were able to maintain a time in range of greater than 75%. "When it comes to the automated insulin delivery system ... I think the sensor matters less and the system matters more," Viral N. Shah, MD, professor of medicine in the division of endocrinology and metabolism and director of diabetes clinical research at Indiana University Center for Diabetes and Metabolic Diseases, said during a presentation. "Having a different sensor with the system, I think the [glycemic] outcomes will still be what you want." I'm including this because the headline here seemed to indicate no CGM makes a difference, but this study only looked at two. https://www.healio.com/news/endocrinology/20260401/switching-cgm-sensors-does-not-impact-glycemic-outcomes-with-automated-insulin-delivery   XX Vitamin D supplementation may help delay or prevent disease progression in people with prediabetes.. in people who have specific variants in their vitamin D receptor gene. This was found after a second look at large study where researchers found vitamin d really did make a difference.. a second look with people who had a specific gene variation had much better results. "More research is needed to see if there are other factors that are associated with risk reduction." https://www.medicalnewstoday.com/articles/vitamin-d-supplements-help-prevent-type-2-diabetes-right-gene-variants   XX Senseonics (Nasdaq:SENS) announced today that it initiated the first European launch of its Eversense 365 continuous glucose monitor (CGM). The launch comes a few months after the company picked up CE mark for the long-term, implantable CGM in January. Eversense 365 is the world's first 365-day CGM system. It also holds clearance as an integrated CGM (iCGM) system, meaning it can work with compatible medical devices. Those include insulin pumps as part of automated insulin delivery systems, like the Sequel Med Tech twiist system. The company said it made Eversense 365 available to the first patients in Sweden. It plans to bring the sensor to Germany, Spain and Italy in the coming weeks https://www.drugdeliverybusiness.com/senseonics-launches-eversense-365-europe/ XX A machine learning model can improve genetic prediction of type 1 diabetes by as much as 10%, show results from a University of California, San Diego study.   The researchers used the machine‑learning model T1GRS to improve on a gold standard polygenic genetic risk score used to predict who is likely to develop the condition called GRS2. The GRS2 polygenic risk score has been widely tested and can be used to predict newborns who are at high risk of developing type 1 diabetes. While early prediction can't necessarily stop the disease it can help to prevent emergencies like diabetic ketoacidosis at diagnosis, allow families time to prepare and could allow use of therapies to delay onset of the condition. In this study, Gaulton and colleagues carried out a genome‑wide association study in 20,355 people with type 1 diabetes and 797,363 non‑diabetic Europeans, as well as a further analysis around the MHC region in 10,107 diabetic and 19,639 nondiabetic individuals. https://www.insideprecisionmedicine.com/topics/molecular-dx/machine-learning-tool-helps-improve-type-1-diabetes-prediction/ XX Sen. Mark Warner (D-Va.) said Monday that he will return to the upper chamber this week after taking time off for the death of his daughter, Madison.   The Virginia senator wrote on the social platform X, "As we remember our incredible daughter, Maddy, my family has been deeply touched by the outpouring of support we've received. Thank you to everyone for your kind words." Madison Warner, 36, died earlier this month after a decades-long battle with juvenile diabetes and other health issues. Mark Warner and his wife, Lisa Collis, wrote in a statement last Monday that they were "heartbroken beyond words" by their daughter's passing.   On Monday, the former Virginia governor said his daughter "was a deeply empathetic and engaged person" and that "as recently as the day she passed, she was full of ideas and suggestions" for him, including how he could improve his social media presence.   "She used to say to me: 'Dad, you have the power — you have to use it.' She pushed me to make the most of my position, to use my seat in the Senate to help people in meaningful ways," he added.       "If I can find any solace during this time, it's that I have the enormous privilege to serve Virginians and the responsibility to keep working for a better, more just world in Maddy's name."   Warner concluded, "I look forward to returning to the Senate this week and continuing that essential work."   Madison Warner is survived by two younger sisters.     An estimated than 2.1 million Americans, including about 314,000 children and adolescents younger than age 20, have diagnosed type 1 diabetes as of March — which is what juvenile diabetes is commonly called — according to the CDC's National Diabetes Statistics Report.   An estimated 11 million U.S. adults have undiagnosed diabetes, the report notes.   Symptoms of type 1 diabetes include feeling more thirsty than usual, urinating a lot, bed-wetting in children who have never done so, feeling very hungry and losing weight without trying, according to the Mayo Clinic. https://thehill.com/homenews/senate/5851605-mark-warner-diabetes-death/ XX Mattel, Inc. and Breakthrough T1D just won a Gold Halo Award for Best Cause Product Initiative for the launch of the first Barbie with T1D.  The Halo Awards recognize the most outstanding corporate social impact efforts over the past year.

Episode 217: Automate Your Lead Generation with our FREE online course: https://go.digitaltrailblazer.com/auto-leads-course-freeMany online business owners eventually hit a wall - whether it's a profit ceiling, misalignment with their audience, or a business model that no longer feels right. Staying stuck in the wrong direction doesn't just kill momentum, it drains your energy and keeps you from building something that truly works.In this episode, Horace Dobson teaches us how to make smart decisions around rebranding and pivoting your business, including how to identify whether you're facing a real alignment problem or just a marketing fix, why finding a unique position in your market eliminates the need to compete on price, and why investing in the right mentorship is the fastest path to breakthrough results.About Horace Dobson: Horace is a registered nurse, disabled U.S. veteran, entrepreneur, and multi-genre author whose life reflects a true rags-to-riches transformation. After nearly 30 years working on hospital floors across the United States, he stepped away from traditional healthcare to found Warrior Weightloss and create Empowered AI - a consumer-focused health-intelligence platform helping people take control of their metabolism, mindset, and longevity through real-world data and accountability, not hype.Beyond business, Horace is deeply committed to service, supporting disabled veterans, foster parents, and families facing food insecurity throughout West Palm Beach County. He is also the author of multiple books spanning health, mindset, and personal transformation — including The Comeback, available free in audiobook form by searching "Horace Dobson The Comeback."Visit Warrior Weightloss here: https://www.warriorweightloss.com/Mention the Digital Trailblazer podcast for 20% off any Weight Loss medications, such as Semaglutide or Tirzepatide at https://www.360lifeshift.comConnect with Horace: Facebook - https://www.facebook.com/profile.php?id=61575535337510 YouTube - https://youtube.com/@evolifewellness?si=aj_CQ0HPM02XppAT LinkedIn - https://www.linkedin.com/in/horace-dobson-ba82a23a/ Instagram - https://www.instagram.com/theempowered.ai/Want to SCALE your online business bigger and faster without the endless hustle of networking, referrals, and pumping out content that nobody sees?Grab our Ultimate Ad Script for Coaches, Agencies, and Course Creators.Learn the exact 5-step script we teach our clients that allows them to generate targeted, high-quality leads at ultra-low cost, so you can land paying customers and clients without breaking the bank on ad spend.Grab the Ultimate Ad Script right HERE - https://join.digitaltrailblazer.com/ultimate-ad-script✅ Connect With Us:Website - https://DigitalTrailblazer.comFacebook - https://www.facebook.com/digitaltrailblazerTikTok: https://www.tiktok.com/@digitaltrailblazerX (Twitter): https://x.com/DgtlTrailblazerInstagram: https://www.instagram.com/DigitalTrailblazer

In this episode, I walk through what's actually happening with generic semaglutide right now—and what it means for you in real life, not just in headlines. I explain where semaglutide fits in the bigger picture, how it compares to tirzepatide, and why generics are entering the market now. I also break down what “bioequivalence” really means—and why that nuance matters when it comes to effectiveness and side effects. I talk about early pricing estimates, what we might see happen with brand-name costs, and how pharmacy-level substitution could impact what patients are actually given. We get into the practical questions I'm already hearing: what the devices will look like, whether dosing will feel the same, and how switching between products might affect different patients. I also share how I'm thinking about this clinically—who will likely transition easily, and who may need a more cautious, individualized approach. And importantly, I address a growing issue: access to medication is not the same as access to care. Obesity treatment is more than a prescription—it's ongoing, structured medical care. Bottom line: I'm genuinely encouraged by the potential for improved access—but your treatment should still be guided by your individual response, not just what's available. This is an evolving space, and I'll keep you updated as we learn more. WORK WITH ME O​​ntario-Wide Virtual Obesity Management Clinic https://www.highmetabolicclinic.com Join my Healthy Lifestyle Coaching Program for women, Best Weight https://www.sashahighmd.com/bestweight Binge Eating Disorder Treatment - https://www.sashahighmd.com/bed Taking the first step toward weight loss can feel overwhelming — but you don't have to do it alone. I've created a curated list of my podcast episodes to gently guide you as you begin your journey. https://www.sashahighmd.com/podcast-guide FOLLOW ME on Instagram - https://www.instagram.com/sashahighmd/

In this episode of The Better Life, Dr. Mary Ann Pinkston sits down with Ray Solano of PD Labs to explore the cutting edge of peptide therapy: transdermal delivery. Moving away from traditional injections, they discuss the science of getting potent peptides like BPC-157, MOTC, and CJC/Ipamorelin into the body through the skin. Solano explains the importance of pharmaceutical quality over "black market" alternatives and reveals a potential breakthrough in topical Semaglutide for metabolic health. From upregulating mitochondria to improving sleep and reducing inflammation, discover how these "magic lotions" are making integrative medicine more accessible and effective. Key Takeaways The Shift to Transdermal: Advancements in specialized bases now allow fragile peptides to bypass the digestive system and needles, absorbing directly into the bloodstream. Mitochondrial & Energy Support: Insights into MOTC for cellular energy and CJC/Ipamorelin for natural growth hormone signaling. Innovation in Weight Management: A discussion on the potential for topical Semaglutide to address "food noise" and metabolic changes without injections. Quality Matters: Why sourcing from a compounding pharmacy is critical to avoid the "moonshine" version of synthetic peptides found online. See omnystudio.com/listener for privacy information.

Welcome to the latest episode (May 2026) of Diabetes Core Update, where every month Neil Skolnik, MD and John Russell, MD review the most important articles on diabetes, obesity, and cardiometabolic disease. This month, they discuss: Marston NA, Bohula EA, Bhatia AK, et al. "Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes: Results From the VESALIUS-CV Trial." JAMA. 2026;335(16):1400–1407. doi:10.1001/jama.2026.3277 Lee YJ, Lee SJ, Kim JW, et al. "Intensive LDL Cholesterol Targeting in Atherosclerotic Cardiovascular Disease." N Engl J Med 2026;394:1365-1375. doi:10.1056/NEJMoa2600283 Nissen SE, Wolski K, D'Alessio D, et al. "Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease: A Post Hoc Analysis of the SURPASS-CVOT Randomized Clinical Trial." JAMA Cardiol. Published online March 28, 2026. doi:10.1001/jamacardio.2026.0767 Moura FA, et al. "Association Between GLP-1 Receptor Agonists and Ischemic Optic Neuropathy: A Meta-analysis." Diabetes Care. 2026;49(5):724–729. doi.org/10.2337/dc25-1238 Ostrominski JW, Ortega-Montiel J, et al. "Comparative Effectiveness of Tirzepatide Versus Dulaglutide or Semaglutide on Major Cardiovascular Events in Type 2 Diabetes and Cardiovascular Disease: Insights From Two Target-Trial Emulations." Diabetes Care. 2026;49(5):808–817 doi.org/10.2337/dc25-3063 Nicole Napoli, "Shingles Vaccine Drastically Cuts Risk of Serious Cardiac Events." The American College of Cardiology. March 17, 2026 https://www.acc.org/About-ACC/Press-Releases/2026/03/16/19/33/Shingles-Vaccine-Drastically-Cuts-Risk-of-Serious-Cardiac-Events For information about the American Diabetes Association's scholarly journals, visit diabetesjournals.org. For more about this podcast, visit About Diabetes Core Update.

GLP-1 drugs like Ozempic and Mounjaro are now everywhere. But what do they actually do beyond weight loss? And what do you need to know before starting them? In this episode, we're joined by Dr Ania Jastreboff, a world-leading researcher at the forefront of GLP-1 treatments and writer of the New York Times bestselling book Enough: Your Health, Your Weight, and What It's Like To Be Free, co-authored with Oprah Winfrey. Dr Jastreboff explains everything you need to know about Ozempic, Mounjaro, Wegovy and other GLP-1 medications for 2026. You'll learn how GLP-1s may reduce the risk of heart disease, improve blood sugar control, and support conditions like sleep apnoea. We also explore why weight often returns after stopping, and what you need to know about Ozempic side effects and long-term use. If these drugs can change how your brain controls hunger, what does that mean for willpower, weight gain, and how we treat obesity long term?

Three years ago, GLP-1 peptides were barely being talked about in the midlife women's health space. Since then, Jessica and I have personally used them, experimented with different approaches, and helped over a thousand women inside our peptide program navigate what works, what backfires, and what women in perimenopause and menopause need to know before jumping in. In this episode, we're pulling back the curtain on our own GLP-1 journeys, including my rough start with Ozempic, why Tirzepatide worked better for me, Jessica's experience with Semaglutide and fatigue, and why Retatrutide is becoming one of the most talked-about peptides right now. We also get into one of the biggest myths floating around online: that GLP-1s automatically cause massive muscle loss. The truth is much more nuanced. We talk about the biggest mistakes we see women making. How Glp1s can impact insulin sensitivity, inflammation, fat cell biology, blood sugar regulation, liver metabolism, and even brain reward pathways. We also dive into some of the peptides we're loving right now beyond GLP-1s, including NAD, KPV, MOTS-c, and Tesamorelin, and why peptide therapy can be powerful when it's used intelligently, not recklessly. This is a real, honest conversation about how to use these tools in a way that supports long-term health, metabolism, muscle, and hormones, instead of chasing fast weight loss at any cost. In this episode, we cover: Our personal three-year journey using GLP-1 peptides Why Ozempic, Semaglutide, Tirzepatide, and Retatrutide can feel very different The truth about GLP-1s and muscle loss Why appetite suppression is not the only sign a GLP-1 is working The biggest mistakes women make with dosing and titration Why protein, amino acids, digestion, and strength training matter so much How GLP-1s may support insulin sensitivity, inflammation, blood sugar, and metabolic health Why some women don't lose weight until thyroid, hormones, food sensitivities, or inflammation are addressed What we're seeing with Retatrutide and why it's getting so much attention Peptides beyond GLP-1s, including NAD, KPV, MOTS-c, and Tesamorelin Who This Episode Is For This episode is for women in perimenopause or menopause who are using GLP-1s, thinking about starting them, or wondering why they are not getting the results they expected. It is especially helpful if you are worried about muscle loss, hair shedding, fatigue, dosing, long-term use, maintenance, or whether peptides are actually supporting your metabolism or just helping you eat less.     Sponsors Join our FREE upcoming masterclass: Why Midlife Weight Gain Won't Budge A smarter way to use GLP-1s in midlife without wrecking muscle or metabolism When: April 30th 11 am PST Register here: https://coaching.karenmartel.com/glp1-masterclass    Add MitoQ Hormonal Metabolic Support to your midlife support toolbox: www.mitoq.com/karenmartel get 10% off your order with code: MARTEL10     Are you in perimenopause or postmenopause and struggling with symptoms—but not getting the support you deserve? At Midlife Solutions, we specialize in hormone optimization for women in midlife. Our all-female clinical team offers telehealth care across all 50 U.S. states, with the ability to prescribe bioidentical estrogen, progesterone, testosterone, and thyroid medication.   Book your FREE Hormone Discovery Call Find out what's really driving your symptoms and what your next best steps are.   Visit the website: https://karenmartel.com   Shop the Midlife Solutions Store Over-the-counter bioidentical hormone creams and oils — no prescription needed. Including: • Progesterone • Estrogen Face Cream • Vaginal Moisturizer and more!   Take the Hormone Quiz Discover hidden hormone imbalances that could be driving your symptoms. Get personalized results (and yes, they may surprise you).   Women's Peptide Weight Loss Program Clinically guided, hormone-aware weight loss for midlife women.   Midlife RESET HRT Program A complete, supportive approach to hormone replacement therapy in midlife.   Your host: Karen Martel Certified Hormone Specialist, Transformational Nutrition Coach, & Weight Loss Expert   Karen's Facebook Karen's Instagram

Most disciplined executives and entrepreneurs aren't struggling with fat loss because of effort or willpower. They're struggling because they're out of sequence—jumping straight to peptides, compounds, and advanced protocols before the three biological levers that actually drive fat loss are even stable.In this episode, Julian Hayes II breaks down the exact three mechanisms that determine whether your body gets lean and stays lean—and how to pull each one in the right direction before layering in anything advanced.You'll walk away understanding why fat loss is a sequencing problem, not a knowledge problem, and what it actually looks like to build a metabolic foundation that performs the way your business does. For executives and entrepreneurs operating in high-stakes environments, this episode connects biology directly to business performance.— Episode Chapter Big Ideas (timing may not be exact) —0:00 – Why disciplined high performers still don't look the part 1:57 – The three biological levers behind sustainable fat loss2:51 – About Julian and Executive Health3:26 – Who this conversation is actually for 4:49 – Lever 1: Nutrient Partitioning: where do your calories actually go?6:04 – The capital allocation analogy: investing in lean tissue vs. storing fat6:50 – The four factors that determine partitioning efficiency12:26 – Practical foundation: how to optimize partitioning before going advanced13:19 – Earning your carbs: the Charles Poliquin philosophy15:30 – GLP-1 receptor agonists and nutrient partitioning15:49 – Testosterone and hormonal optimization: Why hormones make everything go18:06 – Lever 2: Recovery Signaling: Where most high performers self-sabotage19:09 – What recovery signaling actually controls in a deficit19:33 – Cortisol21:02 – Growth hormone22:07 – Thyroid conversion: the T4 to T3 problem nobody talks about24:15 – HRV: your autonomic nervous system's engine light27:07 – Practical recovery: sleep timing and maximizing slow-wave GH pulses28:53 – Protein in a deficit: the primary defense against muscle loss29:39 – Electrolytes, magnesium, and why micronutrients matter more on GLPs32:51 – Advanced layer: CJC-1295 and Ipamorelin34:17 – Exogenous HGH: beyond bodybuilding34:54 – BPC-157 and TB-500: the gateway peptides for recovery35:58 – The 90/95 rule: foundation is the work, advanced tools are the amplifier36:34 – Lever 3: Appetite and Energy Regulation: the compliance lever37:22 – Why fat loss is a compliance problem, not a knowledge problem37:34 – Food noise is biological, not psychological38:51 – What poor appetite regulation actually costs executives40:24 – How aggressive deficits suppress testosterone41:15 – Performance as the feedback loop for energy regulation43:00 – Fiber, gut health, and natural GLP-1 secretion44:06 – Meal timing and circadian biology46:52 – Advanced layer: Semaglutide, Tirzepatide, and Retatrutide explained50:30 – Muscle loss, GI risk, and why lifestyle habits are the real variable51:24 – Genetics and fat loss52:47 – Low-dose Naltrexone54:19 – Thymosin Alpha-1 and emerging peptide research on energy regulation55:36 – Tying it all together: Foundation First, Amplification Second57:01 – The cost of skipping a sequence59:05 – The executive case for fat loss beyond aesthetics1:01:30 – How to work with Julian privately— Connect with Julian and Executive Health —LinkedIn — https://www.linkedin.com/in/julianhayesii/X — https://x.com/thejulianhayesReady to take your health, leadership, and performance to the next level? Book an exploratory call —https://www.executivehealth.io/contactWebsite — https://www.executivehealth.io/***DISCLAIMER: The information shared is not meant to treat or diagnose any condition. This is for educational, informational, and entertainment purposes. The content here is not intended to replace your relationship with your doctor and/or medical practitioner. Consult your provider before making any decisions.

Two-drug, single-tablet approved to replace current antiretroviral regimen; Dupixent approved for pediatric CSU; novel treatment significantly improves survival in metastatic pancreatic cancer; oral semaglutide for adolescents; GLP-1 Fast Tracked for knee osteoarthritis.

Is oatmeal healthy?I have a higher-than-normal carotid artery intima-media thickness and no appreciable plaque. Should I be concerned?Should my husband and I take the hepatitis B vaccine?

Microdosing GLP-1 agonists can create powerful shifts in your body—when they're used the right way. The problem? Most people (and even many doctors) are using them as a quick-fix weight loss tool. And when that's the approach, of course you see burnout, terrible side effects, and rebound weight gain. But that doesn't mean these compounds are the problem. It means the strategy is. When used in a microdosing approach, GLP-1 agonists can support your body on a much deeper level—helping improve insulin sensitivity, reduce inflammation, and calm an overworked nervous system. Especially if your body has been stuck in chronic stress or survival mode, this can be the missing piece that allows your system to finally feel safe enough to function differently. This isn't about forcing weight loss. It's about creating the internal environment where your body can release it. You don't have to stay on these forever. You don't have to suffer through harsh side effects. But you do need a more intentional, supportive approach. In this episode, I'll show you what that actually looks like. When you're ready to release the extra weight for good—and finally support your nervous system, metabolism, and relationship with food—it's time to have a conversation. Schedule your free consultation to explore what working together could look like, and whether my 3-part process is the right fit for you. www.bodyyoucrave.com/schedule  Chapters (00:00:02) - Hungry for Love(00:00:26) - Gaining Weight With GLP1s(00:06:21) - Turning off your brain: The process(00:06:56) - Tirzepatide and Semaglutide:(00:12:39) - Microdose for Perimenopausal and Menopausal Women in Their 60(00:21:04) - How to Lose Weight With a Strategic Approach(00:22:06) - Pregnant women on GLP1s(00:29:58) - How to manage emotional eating with GLP1(00:33:17) - How to Break the Cycle Around Binge Eating

 Ozempic. Semaglutide. GLP-1s. Everyone's talking about them — but nobody's telling you the whole truth. Dr. Tabatha sits down with functional medicine physician Dr. Rika to break down what peptides actually are, who should be on GLP-1s, and what happens when you stop. What a peptide actually is — in plain EnglishHow your body makes over 7,000 peptides and what happens as they declineGLP-1s explained: how they work, who they're for, who they're not forThe shocking muscle loss stats nobody tells you before you startWhy gut health determines how well GLP-1s work — and your side effectsThe difference between semaglutide, tirzepatide, and what's coming nextHow to come off GLP-1s without reboundingMicrodosing for inflammation, brain health, and heart protectionWhy postmenopausal women lose less weight on GLP-1s without hormonesToxins stored in fat cells — and why they block weight lossMetabo Lift: the natural herbal supplement that boosts your body's own GLP-1 by 55%Resources: Dr. Rajka's Book: https://amzn.to/4t6ZWjp Free Longevity Quiz → thelongevityscore.com Metabo Lift → shop.fasttofaith.com/product/metabo-lift/ Use code PODCAST for 20% offTIMESTAMPS00:00 — "Aging is inevitable. Decline doesn't have to be." 00:13 — Welcome to Fast to Faith 01:26 — Introducing Dr. Rika: the go-to doctor for doctors 02:51 — Why doctors come to Dr. Rika for help 04:36 — What is a peptide? The biologic text message explained 07:23 — Does your body make peptides naturally? 08:15 — What is a GLP-1 and how does it work? 09:12 — The danger of buying GLP-1s online 09:31 — Who should be on a GLP-1 — and who shouldn't 11:10 — GLP-1s as band-aid medicine — what happens when you stop 12:21 — Muscle loss: the shocking stat nobody tells you 12:51 — Semaglutide vs. tirzepatide vs. what's coming next 13:44 — GI side effects and the gut foundation that prevents them 16:33 — The real cost of going on GLP-1s without laying the foundation 18:11 — Metabo Lift: naturally boosting your own GLP-1 by 55% 20:27 — Muscle loss, bone loss, and what you must do while on GLP-1s 22:58 — Why root causes are never addressed in online clinics 23:23 — What does coming off GLP-1s actually look like? 24:58 — Microdosing GLP-1s: benefits for inflammation, brain, and heart 27:35 — How long should you stay on them? 28:48 — Fat cells store toxins — and that's why you can't lose weight 31:52 — Genetics, detox pathways, and who needs deeper testing 33:31 — Dr. Rika's glutathione moment that changed everything 35:56 — Growth hormone peptides and what's coming for longevity 38:34 — Oral vs. injectable peptides — what we know 38:60 — How to find and work with Dr. Rika 40:48 — Closing: Proverbs 3:7-8Ready to stop trying harder and start healing smarter? Start with the $5 Faith Reset Challenge — your first step to regulating your nervous system, stabilizing your metabolism, and reconnecting with your identity in Christ through simple, faith-centered rhythms. This is where most women begin. 

GLP-1 medications like semaglutide and tirzepatide are everywhere right now—but are they actually solving the problem? In Episode 8 of this 16-part series on ultra-processed foods, Dr. Brendan McCarthy breaks down the truth about GLP-1 medications: how they work, why they can feel like a “miracle,” and where things go wrong when they're used without proper medical guidance. This isn't about shame. It's about understanding. GLP-1s can quiet “food noise” and help regulate appetite—but they don't fix your relationship with food, your metabolism, or the long-term patterns that lead to weight gain. Without structure, nutrition, and proper care, many patients end up with muscle loss, nutrient deficiencies, and rebound weight gain. In this episode, you'll learn: What GLP-1 medications actually do in your body Why they're not a long-term solution on their own The biggest mistakes doctors and clinics make when prescribing them How ultra-processed foods drive weight gain in the first place How to use GLP-1s the right way to create lasting change The goal isn't dependence—it's freedom. If you're currently on a GLP-1 (or considering it), this episode will change how you think about your treatment plan.   Mechanism Anchored References This episode is not anti medication. It is about putting GLP 1 therapy in its proper place. GLP 1 receptor agonists can reduce appetite pressure and alter satiety signaling. That matters. But quieter appetite is not the same as full recovery. Food quality still matters. Protein still matters. Muscle still matters. Structure still matters.   References U.S. Food and Drug Administration. WEGOVY semaglutide injection Prescribing Information. 2025. Wilding, John P H, et al. Once Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, vol. 384, no. 11, 2021, pp. 989 to 1002. Wilding, John P H, et al. Weight Regain and Cardiometabolic Effects After Withdrawal of Semaglutide The STEP 1 Trial Extension. Diabetes Obesity and Metabolism, vol. 24, no. 8, 2022, pp. 1553 to 1564. Hall, Kevin D, et al. Ultra Processed Diets Cause Excess Calorie Intake and Weight Gain An Inpatient Randomized Controlled Trial of Ad Libitum Food Intake. Cell Metabolism, vol. 30, no. 1, 2019, pp. 67 to 77. Neeland, Ian J, et al. Changes in Lean Body Mass with Glucagon Like Peptide 1 Based Therapies and Mitigation Strategies. Diabetes Obesity and Metabolism, 2024. Wilding, John P H, et al. Impact of Semaglutide on Body Composition in Adults with Overweight or Obesity Exploratory Analysis of the STEP 1 Study. 2021. Everitt, Barry J, and Trevor W Robbins. Drug Addiction Updating Actions to Habits to Compulsions Ten Years On. Annual Review of Psychology, vol. 67, 2016, pp. 23 to 50. Monteiro, Carlos A, et al. The UN Decade of Nutrition the NOVA Food Classification and the Trouble with Ultra Processing. Public Health Nutrition, vol. 21, no. 1, 2018, pp. 5 to 17.   Dr. Brendan McCarthy is the founder and Chief Medical Officer of Protea Medical Center in Arizona. With over two decades of experience, he's helped thousands of patients navigate hormonal imbalances using bioidentical HRT, nutrition, and root-cause medicine. He's also taught and mentored other physicians on integrative approaches to hormone therapy, weight loss, fertility, and more. If you're ready to take your health seriously, this podcast is a great place to start.  

Unwanted body habitus changes among people living with HIV receiving antiretroviral therapy (ART) can negatively affect physical and mental health and may even affect ART adherence. Listen to learn from experts Grace A. McComsey, MD, FIDSA, and Richard A. Elion, MD, how to identify people who may be candidates for pharmacologic weight interventions, and hear firsthand from patient advocates how unwanted weight gain impacts their daily life. Topics covered include: The burden of unwanted weight gain among people living with HIV  Potential causes for unwanted weight gain Available pharmacologic agents for weight loss  Clinical trial data supporting pharmacologic agents for weight loss in people living with HIV Patient advocate perspectives Get access to all of our new podcasts by subscribing to the Decera Clinical Education Infectious Diseases Podcast on Apple Podcasts, YouTube Music, or Spotify. Link to full program: https://bit.ly/4cpeJ1I Presenters: Richard A. Elion, MD Clinical Professor of Medicine George Washington University School of Medicine Washington, DC Grace A. McComsey, MD, FIDSA Vice Dean for Clinical and Translational Research Director, Clinical and Translational Science Institute (CTSI) Principal Investigator, Clinical and Translational Science Collaborative (CTSC) of Northern Ohio Gertrude Chandler Tucker Professor of Pediatrics and Medicine Case Western Reserve University Research Integrity Officer Senior Faculty, Pediatric and Adult Infectious Diseases University Hospitals Health System Cleveland, Ohio Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Send us Fan MailThis week, I'm taking a curious, watch-and-see approach to GLP-1 medications—things like semaglutide, Ozempic, Wegovy. We'll cover the research-backed potential benefits, the side effects, what happens after stopping, and why the conversation is about much more than just weight. No judgment, no pressure, just information, reflection, and a reminder that your choices are personal and worth considering thoughtfully.Tune in if you want to explore GLP-1 medications from a place of curiosity and clarity.Quote of the Week:“We are what we repeatedly do. Excellence, then, is not an act, but a habit.” — Will Durant Citations1.    Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384, 989–1002.2.    Rubino, D., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance. Diabetes, Obesity and Metabolism.3.    SELECT Trial Investigators (2023). Semaglutide and Cardiovascular Outcomes in Obesity. New England Journal of Medicine.4.    Drucker, D. J. (2018). Mechanisms of Action and Therapeutic Application of GLP-1. Cell Metabolism.5.    Baggio, L. L., & Drucker, D. J. (2007). Biology of Incretins. Gastroenterology.Let's go, let's get it done.Get more information at: http://projectweightloss.org

In this episode, we discuss the most important annual updates in the American Diabetes Association Guidelines, Standards of Care 2026, particularly focusing on changes in pharmacotherapy recommendations and the supporting evidence. Key Concepts A few existing agents now have ASCVD risk reduction data in patients with existing ASCVD or high indicators for ASCVD. They are: oral semaglutide and tirzepatide.  SGLT2is are still first-line in patients with diabetes and HF including HFpEF, but SC semaglutide and tirzepatide are now recommended for those with symptomatic HFpEF and obesity due to positive outcomes in this population. The GLP-1RA and dual GLP-1/GIP RA are the preferred agents for weight management in patients with T2DM, but use of GLP-1RA can be considered for weight loss in patients with T1DM. The guideline also better defines recommendations for medication-induced hyperglycemia from immune checkpoint inhibitors, PI3Kɑ (phosphoinositidylinositol 3-kinase α) inhibitors, mTOR inhibitors, and steroids.  References American Diabetes Association. Standards of care in diabetes—2026. Diabetes Care. 2026;49(suppl 1):S1-S377. SOUL study. Darren K. McGuire, Marx N, Mulvagh SL, et al. Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes. N Engl J Med. 2025;392(20):2001-2012. doi:10.1056/NEJMoa2501006. SURPASS-CVOT. Nicholls SJ, Pavo I, Bhatt DL, et al. Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes. N Engl J Med. 2025;393(24):2409-2420. doi:10.1056/NEJMoa2505928. SUMMIT. Packer M, Zile MR, Kramer CM, et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med. 2025;392(5):427-437. doi:10.1056/NEJMoa2410027. STEP-HFpEF. Kosiborod MN, Abildstrom SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389(12):1069-1084. doi:10.1056/NEJMoa2306963. STEP-HFpEF DM. Kosiborod MN, Petrie MC, Borlaug BA, et al. Semaglutide in patients with obesity‑related heart failure and type 2 diabetes. N Engl J Med. 2024;390(15):1394‑1407. doi:10.1056/NEJMoa2313917.

The feud between Novo Nordisk (NYSE:NVO) and Hims & Hers (NYSE:HIMS) has been one of the most dramatic storylines in biotech investing — and it just took a major new turn. Simon Erickson breaks down the four-year saga: from Wegovy's launch and the FDA shortage list, to compounded Semaglutide flooding the market at a fraction of the cost, to patent infringement lawsuits, and finally to the new distribution agreement signed March 9, 2026.We cover the explosive growth potential of GLP-1 weight loss drugs, why the global weight loss drug market could hit $200 billion — double the size of the diabetes market — and what the new Wegovy oral pill means for both companies and investors. We also examine how Eli Lilly (NYSE:LLY) fits into the competitive picture with Zepbound and why its U.S.-based advantage has translated into stronger investor sentiment compared to Novo.Simon shares his investor takeaways: Novo's pricing power is under pressure, the IP battle is far from over, and new CEO Mike Doustdar appears to be taking a harder line on patent enforcement. Meanwhile, Hims & Hers emerges from this feud with greater clarity on what it can and can't sell — and the patent infringement overhang on its stock has been lifted.STOCKS MENTIONED:Novo Nordisk (NYSE:NVO)Hims & Hers (NYSE:HIMS)Eli Lilly (NYSE:LLY)#NovoNordisk #nvo #HimsAndHers #hims #GLP1 #Semaglutide #Wegovy #WeightLossDrugs #Zepbound #EliLilly #InvestingNews #PharmaceuticalStocks #BiotechInvesting #StockMarket #GLP1Stocks #CompoundingSemaglutide #WeightLoss #7investing #Simonerickson

Are you on tirzepatide or semaglutide and struggled with inconsistent weight loss and side effects? On this episode of On The Pen, Dave Knapp and Dr. Ian Ellis dive into the surprising variability of GLP-1 dosing (retatrutide, tirzepatide), even when the weekly dose remains the same. We explore how these subtle dosage changes can lead to frustrating glp-1 side effects and why many individuals eventually give up on their weight loss medication. This new way of thinking about glp-1 dosing could change the obesity medicine game. Referenced Links: http://www.OTPLinks.com00:00 Why most GLP-1 users are never on the same dose twice01:55 Dr. Ian's background: trainer, nutritionist, ER physician04:00 His obsessive relationship with food and body composition07:45 The two impossible choices: obsession or obesity10:12 How medical school destroyed his health10:25 A colleague mentions Ozempic for the first time11:35 His first dose and what real satiety feels like13:00 Why the same dose felt worse every single week15:00 30 lbs lost but the body scan results were horrifying17:30 Why elderly patients are especially at risk on GLP-1s18:35 Patient case: Pat May, 310 lbs, lost over 100 lbs20:45 Semaglutide half-life and dose stacking explained24:50 The therapeutic window and finding your ideal level26:30 Why the dosing protocol was built for trials not people28:00 You are never on the same drug level twice29:00 Patient case: Mary Alice lost 30 lbs below the starting dose32:00 The math behind calculating your precise GLP-1 level35:00 The VoaFit app and making precision dosing scalable36:00 Their patients lost more weight using half the medicine39:30 Why 40 to 70 percent of people quit GLP-1s42:00 Compounding pharmacies and the case for flexible dosing46:00 Using GLP-1 as a thermostat dial for your appetite56:45 Where precision dosing is available now58:30 Beyond GLP-1s: applying this to testosterone and more1:05:30 Why hitting the dose ceiling kills long-term results1:07:00 Dr. Ian's outcome: off GLP-1s completely1:10:00 Fixing a broken one-size-fits-all dosing paradigm1:13:00 How to find Dr. Ian Ellis and VoaFit

In this episode, we explore a surprising new contender in the fight against alcohol use disorder — semaglutide. Could the blockbuster weight-loss drug also curb heavy drinking? We examine the first randomized controlled trial testing this GLP-1 receptor agonist specifically for AUD. Faculty: David A. Gorelick, M.D., Ph.D., D.L.F.A.P.A., F.A.S.A.M. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CMEs: Quick Take Vol. 79 Semaglutide for Alcohol Use Disorder: New RCT Data

Colorectal cancer is now the No.1 cause of death for people under 50 in the United States. When it is caught early, nine out of ten people survive. When it is caught late, only two out of ten do. Yet most people are not screening, not eating enough fiber, and have no idea how rapidly the gut microbiome is collapsing in modern populations. I sat down with Dr. Karan Rajan, NHS surgeon, gut health expert, and founder of Loam Science, to break down the real biology behind the gut microbiome and why it may be one of the most powerful levers we have for longterm health. We cover the rising colorectal cancer epidemic in young people, why fiber is the single most important thing you can do for your colon, and how the microbiome connects to your brain, heart, hormones, immune system, and even your skin. Dr. Karan also explains how stress, poor sleep, NSAIDs, antibiotics, and proton pump inhibitors silently destroy the gut lining, why the carnivore diet starves your microbiome, the emerging link between gut health and endometriosis, and what the science actually says about microbiome testing, GLP-1 peptides, and supplement quality. Reduce your risk of Alzheimer's with my science-backed protocol for women 30+: https://go.neuroathletics.com.au/youtube-sales-page Subscribe to The Neuro Experience for evidence-based conversations at the intersection of brain science, longevity, and performance. _____ TOPICS DISCUSSED 00:00 Colorectal Cancer Is Now the #1 Killer Under 50 01:24 Why Early Screening Changes Everything 03:19 The Gut Microbiome Explained Simply 05:51 Why Fiber Is the Rent for Your Colon 11:32 The Hadza Tribe and What 100g of Fiber a Day Does 18:45 The Carnivore Diet and What It Does to Your Gut 24:10 Stress, the Vagus Nerve, and Gut Dysfunction 31:20 Sleep, Circadian Clocks, and Your Bowel Health 33:06 The Gut-Cancer Connection 34:12 Cholesterol, the Gut-Heart Axis, and LDL 38:50 Estrogen, Perimenopause, and the Microbiome 43:15 Endometriosis and the Microbiome Trial 48:30 Leaky Gut, NSAIDs, Antibiotics, and PPIs 53:25 GLP-1 Peptides, Semaglutide, and What the Research Says 55:38 Why Supplement Quality Is Mostly Unregulated _______ Thank you to our sponsors Function Health: https://www.functionhealth.com/louisanicola Timeline: http://timeline.com/NEURO Wayfair: https://www.wayfair.com/ Cheers Health: https://CheersHealth.com/NEURO Use code NEURO for 20% off Jones Road Beauty: https://www.jonesroadbeauty.com Use code NEURO BASED Bodyworks: https://basedbodyworks.com/ Use code NEURO for 20% off _______ I'm Louisa Nicola - clinical neurophysiologist - Alzheimer's prevention specialist - founder of Neuro Athletics. My mission is to translate cutting-edge neuroscience into actionable strategies for cognitive longevity, peak performance, and brain disease prevention. If you're committed to optimizing your brain- reducing Alzheimer's risk - and staying mentally sharp for life, you're in the right place. Stay sharp. Stay informed. Join thousands who subscribe to the Neuro Athletics Newsletter → https://bit.ly/3ewI5P0 Instagram: https://www.instagram.com/louisanicola_/ Twitter : https://twitter.com/louisanicola_ Learn more about your ad choices. Visit megaphone.fm/adchoices

Dr. Spencer Nadolsky, Dr. Karl, and chief science officer Dr. Grant Tinsley sit down with Dr. Stephen Heymsfield, physician at the Pennington Biomedical Research Center and lead author on the BELIEVE trial, to break down what happens when you combine bimagrumab with semaglutide and why over 90 percent of weight lost in the combination group was pure fat. Dr. Heymsfield has published over 600 peer reviewed articles and is widely considered one of the foremost body composition researchers in the world, and Grant Tinsley credits him as a foundational influence on his own work in the field. In this episode they cover what bimagrumab actually is and how blocking the activin receptor causes muscle to grow, the origin story of the drug from Novartis to Versanus to Lilly and why sarcopenia research accidentally opened the door to obesity treatment, the nine group trial design and what it really boils down to, why the bimagrumab only group lost 7 percent of their weight entirely as fat without reducing food intake, the LDL cholesterol finding that has everyone talking and whether it actually matters, what happens to muscle and weight when you come off both drugs, why visceral adipose tissue practically disappeared in the antibody treated groups, the functional outcomes data including grip strength and physical activity scales, whether a subcutaneous version is coming, and what the future of this drug class looks like now that Lilly has deprioritized it. The Docs Who Lift podcast distills and simplifies the complexities of exercise, medicine, and weight loss. Subscribe so you never miss an episode. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

GLP-1 medications like semaglutide are often talked about as weight-loss drugs, but the science is revealing a much bigger story. In the first of this two-part discussion, Stacy welcomes back clinical nutritionist and author Jessica Brown to explore what research is actually showing about GLP-1 medications and whole-body health. They unpack emerging science around inflammation, immune regulation, metabolic health, and gut function, and why these medications may impact far more than weight. Stacy shares her own experience starting a GLP-1 medication and the mindset shift that comes with re-examining long-held beliefs about diet culture, intuitive eating, and health. For Stacy's full story and references, find show notes at realeverything.com. Find Jessica: thelovingdiet.com instagram.com/thelovingdiet youtube.com/c/TheLovingDiet tiktok.com/@thelovingdiet Find Stacy: ⁠realeverything.com⁠ realeverything.com/shaklee instagram.com/realstacytoth missionmakersart.com missionalchemists.com Learn more about your ad choices. Visit megaphone.fm/adchoices

Join us as we review and appraise recent practice-changing articles on oral semaglutide for obesity, fish oil in ESRD, IV iron during infection, the new US Dietary Guidelines, & anticoagulation after ablation in AFib. Fill your brain hole with a delicious stack of hotcakes! Featuring Paul Williams (@PaulNWilliamz), Rahul Ganatra (@rbganatra), Josh Gilman, & Matt Watto (@doctorwatto).Claim CME for this episode at curbsiders.vcuhealth.org!Patreon | Episodes | Subscribe | Spotify | YouTube | Newsletter | Contact | Swag! | CMECredits Written and Hosted by: Rahul Ganatra MD, MPH; Paul Williams, MD, FACP, Joshua Gilman, MD, & Matthew Watto MD, FACP Cover Art: Rahul Ganatra, MD MPH Reviewer: Emi Okamoto, MD Technical Production: Pod Paste Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP Show Segments Intro, disclaimer Oral Semaglutide for obesity Fish Oil for CV risk reduction in hemodialysis patients IV Iron for iron deficiency anemia during infection New USA Dietary Guidelines Anticoagulation after catheter ablation for AF Outro Sponsor: FIGSCheck out the limited-edition Team USA collection, and get 15 percent off your first order at Wearfigs.com with code FIGSRX. Sponsor: Continuing Education CompanyVisit CMEmeeting.org/curbsiders and use promo code Curb30 for 30% off all online courses and webcasts.  Sponsor: GustoTry Gusto today at gusto.com/CURB, and get three months free when you run your first payroll.Sponsor: MDProgress For our listeners, enjoy your first month free at mdprogress.ca/promo/curbsiders